DK1379253T3 - Fremgangsmåde til fremstilling og anvendelse af farmaceutiske formuleringer omfattende 7alfa, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-on og 17-estere heraf - Google Patents

Fremgangsmåde til fremstilling og anvendelse af farmaceutiske formuleringer omfattende 7alfa, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-on og 17-estere heraf

Info

Publication number
DK1379253T3
DK1379253T3 DK02728620T DK02728620T DK1379253T3 DK 1379253 T3 DK1379253 T3 DK 1379253T3 DK 02728620 T DK02728620 T DK 02728620T DK 02728620 T DK02728620 T DK 02728620T DK 1379253 T3 DK1379253 T3 DK 1379253T3
Authority
DK
Denmark
Prior art keywords
dien
esters
dimethyl
preparation
7alpha
Prior art date
Application number
DK02728620T
Other languages
Danish (da)
English (en)
Inventor
Pemmaraju Narasimha Rao
Carmie Kirk Acosta
Richard P Blye
Hyun K Kim
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/010293 external-priority patent/WO2001074839A2/en
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1379253T3 publication Critical patent/DK1379253T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK02728620T 2001-03-30 2002-03-29 Fremgangsmåde til fremstilling og anvendelse af farmaceutiske formuleringer omfattende 7alfa, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-on og 17-estere heraf DK1379253T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/010293 WO2001074839A2 (en) 2000-03-31 2001-03-30 Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use

Publications (1)

Publication Number Publication Date
DK1379253T3 true DK1379253T3 (da) 2006-06-26

Family

ID=21742454

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02728620T DK1379253T3 (da) 2001-03-30 2002-03-29 Fremgangsmåde til fremstilling og anvendelse af farmaceutiske formuleringer omfattende 7alfa, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-on og 17-estere heraf

Country Status (7)

Country Link
EP (1) EP1379253B1 (de)
JP (1) JP2005510541A (de)
AT (1) ATE321557T1 (de)
DE (1) DE60210268T2 (de)
DK (1) DK1379253T3 (de)
ES (1) ES2261665T3 (de)
WO (1) WO2003045398A1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA712312B (en) * 1970-04-28 1972-01-26 Ochsner Med Found Alton 4,14-estradiene compounds
TW548277B (en) * 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens

Also Published As

Publication number Publication date
DE60210268T2 (de) 2006-12-07
WO2003045398A1 (en) 2003-06-05
WO2003045398A8 (en) 2004-02-19
DE60210268D1 (de) 2006-05-18
ES2261665T3 (es) 2006-11-16
EP1379253B1 (de) 2006-03-29
ATE321557T1 (de) 2006-04-15
EP1379253A1 (de) 2004-01-14
JP2005510541A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
PL400027A1 (pl) Wieloelementowa farmaceutyczna postac dawkowania i sposób jej wytwarzania
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
PT1412384E (pt) Formulação estável de glp-1 modificado
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
IS6892A (is) Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munn
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
SE0100901D0 (sv) New composition
HUP0301789A2 (hu) Rekombináns anti CD40 ellenanyagok és használatuk
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
DK1280799T3 (da) Orthosubstituerede anthranilsyreamider og anvendelse heraf som lægemidler
IS8051A (is) Kladríbínefnablöndur til inngjafar um munn
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
HUP0203295A2 (hu) Emphysema kezelése RAR-szelektív retinoid agonistákat tartalmazó gyógyszerkészítmények felhasználásával
ATE432068T1 (de) Cetirizin und pseudoephedrin enthaltende tablette
IS7266A (is) Lyfjaform sem innihalda sýru-óþolin virk efni og aðferðir til tilreiðslu þeirra
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
HK1060850A1 (en) Pharmaceutical composition for treatment of phimosis using topical corticosteroid
ATE294181T1 (de) (3,4-a:3,4-c)carbazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
DK1379253T3 (da) Fremgangsmåde til fremstilling og anvendelse af farmaceutiske formuleringer omfattende 7alfa, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-on og 17-estere heraf
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
NO20034985D0 (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav